Original Article

You have full text access to this OnlineOpen article

Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?†

Meta-Analysis of Randomized Trials

  1. Emilio Bria MD1,‡,§,*,
  2. Federica Cuppone MD1,‡,
  3. Diana Giannarelli PhD2,
  4. Michele Milella MD1,
  5. Enzo Maria Ruggeri MD3,
  6. Isabella Sperduti PhD2,
  7. Paola Pinnarò MD1,
  8. Edmondo Terzoli MD1,
  9. Francesco Cognetti MD1,
  10. Paolo Carlini MD1

Article first published online: 29 MAY 2009

DOI: 10.1002/cncr.24392

Issue

Cancer

Cancer

Volume 115, Issue 15, pages 3446–3456, 1 August 2009

Additional Information

How to Cite

Bria, E., Cuppone, F., Giannarelli, D., Milella, M., Ruggeri, E. M., Sperduti, I., Pinnarò, P., Terzoli, E., Cognetti, F. and Carlini, P. (2009), Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?. Cancer, 115: 3446–3456. doi: 10.1002/cncr.24392

Author Information

  1. 1

    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy

  2. 2

    Biostatistics, Regina Elena National Cancer Institute, Rome, Italy

  3. 3

    Medical Oncology, Hospital “Belcolle”, Viterbo, Italy

  1. ‡

    The first 2 authors contributed equally to this article.

  2. §

    Fax: (011) 390652666219

*Department of Medical Oncology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy

  1. †

    Presented and awarded at the Presidential Symposium of the 31st European Society for Medical Oncology Congress, Istanbul, Turkey, September 29-October 3, 2006. Preliminary data presented at the 42nd American Society of Medical Oncology annual meeting, Atlanta, Georgia, June 2-6, 2006.

Publication History

  1. Issue published online: 20 JUL 2009
  2. Article first published online: 29 MAY 2009
  3. Manuscript Accepted: 6 JAN 2009
  4. Manuscript Revised: 5 JAN 2009
  5. Manuscript Received: 11 DEC 2008

Funded by

  • National Ministry of Health and the Italian Association for Cancer Research

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (361K)

References

  • 1
    Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005; 294: 238-244.
  • 2
    Chuba PJ, Moughan J, Forman JD, Owen J, Hanks G. The 1989 patterns of care study for prostate cancer: 5-year outcomes. Int J Radiat Oncol Biol Phys. 2001; 50: 325-334.
  • 3
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
    Direct Link:
  • 4
    Roach M3rd, Lu J, Pilepich MV, et al. Predicting long-term survival, and the need for hormone therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys. 2000; 47: 617-627.
  • 5
    Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360: 103-106.
  • 6
    D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004; 292: 821-827.
  • 7
    Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005; 6: 841-850.
  • 8
    Laverdiere J, Nabid A, De Bedoya LD, et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol. 2004; 171: 1137-1140.
  • 9
    Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001; 50: 1243-1252.
  • 10
    Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005; 61: 1285-1290.
  • 11
    Roach M3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008; 26: 585-591.
  • 12
    See WA, Tyrrell CJ. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin Oncol. 2006; 132( suppl 1): S7-S16.
  • 13
    D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008; 299: 289-295.
  • 14
    Bolla M, Collette L, Van Tienhoven, G, et al. Ten-year results of long-term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: a phase III EORTC Study. Int J Radiat Oncol Biol Phys. 2008; 72: S30-S31.
  • 15
    Denham JW, Steigler A, Wilcox C, et al. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol. 2008; 9: 1058-1068.
  • 16
    Pignon JP, Hill C. Meta-analyses of randomised clinical trials in oncology. Lancet Oncol. 2001; 2: 475-482.
  • 17
    Bria E, Nistico C, Cuppone F, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer. 2006; 106: 2337-2344.
    Direct Link:
  • 18
    Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Intervention 4.2.6. The Cochrane Library, Issue 4. Chichester, UK: John Wiley & Sons, Ltd.; 2006.
  • 19
    Case LD, Kimmick G, Paskett ED, Lohman K, Tucker R. Interpreting measures of treatment effect in cancer clinical trials. Oncologist. 2002; 7: 181-187.
  • 20
    Bria E, Gralla RJ, Raftopoulos H, et al. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. Lung Cancer. 2009; 63: 50-57.
  • 21
    Parmar MKB, Machin D. Survival Analysis: A Practical Approach. Chichester, UK: John Wiley & Sons, Ltd.; 1995.
  • 22
    Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998; 317: 1309-1312.
  • 23
    Bolla M, van Tienhoven G, de Reijke TM, et al. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT—Results of the randomized EORTC phase III trial 22961 [abstract]. J Clin Oncol. 2007; 25( 18 suppl): 5014.
  • 24
    Crook J, Ludgate C, Malone S, et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 60: 15-23.
  • 25
    Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008; 26: 2497-2504.
  • 26
    Djulbegovic B, Soares HP, Kumar A. What kind of evidence do patients and practitioners need: evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms. Cancer Treat Rev. 2006; 32: 572-576.
  • 27
    Soares HP, Kumar A, Djulbegovic B. Evidence profiles for breast cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev. 2007; 33: 87-89.
  • 28
    De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008; 26: 44-53.
  • 29
    Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26: 3552-3559.
  • 30
    Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A. Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with 3-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2005; 62: 397-405.
  • 31
    Martinez AA, Demanes DJ, Galalae R, et al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys. 2005; 62: 1322-1331.
  • 32
    Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007; 8: 475-487.
  • 33
    D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007; 25: 2420-2425.
  • 34
    Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009; 27: 92-99.
  • 35
    Smith MR, Bae K, Efstathiou JA, et al. Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. J Clin Oncol. 2008; 26: 4333-4339.
  • 36
    Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007; 99: 1516-1524.
  • 37
    Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 2009; 35: 9-17.
  • 38
    Piedbois P, Buyse M. Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol. 2004; 22: 3839-3841.
  • 39
    Bria E, Gralla RJ, Raftopoulos H, Giannarelli D. Comparing 2 methods of meta-analysis in clinical research—individual patient data-based (IPD) and literature-based abstracted data (AD) methods: analyzing 5 oncology issues involving more than 10,000 patients in randomized clinical trials (RCTs) [abstract]. J Clin Oncol. 2007; 25( 18 suppl): 6512.
View Full Article (HTML) Get PDF (361K)